Uterine Serous Carcinoma
Oncology
2
Pipeline Programs
1
Companies
2
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 1 programs with unclassified modality
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Zentalis PharmaceuticalsSAN DIEGO, CA
2 programs2
AzenosertibPhase 2Small Molecule1 trial
ZN-c3Phase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
Zentalis PharmaceuticalsAzenosertib
Zentalis PharmaceuticalsZN-c3
Clinical Trials (2)
Azenosertib in Uterine Serous Carcinoma: Biomarker Study
Start: Mar 2025Est. completion: Jan 2028
Phase 2Recruiting
A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma
Start: Jul 2021Est. completion: May 2025
Phase 2Recruiting
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
9m ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
9m ago
Office Administrator
SystImmune
9m ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
20m ago
Working Student Office Management Support (m/f/d)
Mindpeak
Hamburg
23m ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
23m ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 actively recruiting trials
Small Molecule is the dominant modality (100% of programs)
1 companies competing in this space